Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Sunshine Guojian Pharmaceutical (Shanghai) Co: Clinical Trials & FDA Approval Profile

Sunshine Guojian Pharmaceutical (Shanghai) Co (Global / Institutional) sponsors 39 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 14 active protocols (9 recruiting now), 10 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)0.0%
Median Closed Enrollment vs National (145 pts)142 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Sunshine Guojian Pharmaceutical (Shanghai) Co
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)39
Active Pipeline (Recruiting Now)14 (9)
Completed vs Stopped Early10 / 0 (0.0%)
Median Closed Actual Enrollment142 participants
Physical Hospital Site Disclosure79.3% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Sunshine Guojian Pharmaceutical (Shanghai) Co
Hospital Research SiteLocationShared Protocols
Shanghai General HospitalShanghai4
Peking University People's HospitalBeijing, Beijing Municipality3
Shenzhen People's HospitalShenzhen, Guangdong2

Explore interactive annual charts and M&A subsidiary rollups in the Sunshine Guojian Pharmaceutical (Shanghai) Co Interactive Dossier, benchmark peers in Immunology, Rheumatology, and Dermatology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI